- $518.26m
- $469.82m
- $0.03m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 20,730.45 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -679436% | ||
Financial Summary
| Year End 30th Jun | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.07 | 0.09 | 0.11 | 0.12 | 0.03 | n/a | 3.79 | -15.8% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. It is engaged in developing novel therapies to treat vision-threatening eye diseases, like wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate in Phase 3 development, sozinibercept, is a first-in-class VEGF-C/D trap inhibitor being evaluated in combination with standard-of-care anti-VEGF-A therapies to deliver superior vision to wet AMD patients. It has initiated two pivotal Phase 3 clinical trials, COAST (Combination OPT-302 with Aflibercept Study) and ShORe (Study of OPT-302 in combination with Ranibizumab), in treatment-naive patients with wet AMD to evaluate the efficacy and safety of sozinibercept in combination with anti-VEGF-A therapies compared to anti-VEGF-A monotherapy. It is advancing its clinical development program of sozinibercept in DME as well as investigating the feasibility of a co-formulation of sozinibercept with a VEGF-A inhibitor.
Directors
- Jeremy Levin NEC (68)
- Megan Baldwin CEO
- Karen Adams VFN
- Richard Chadwick OTH
- Mike Gerometta OTH
- Annette Leahy OTH
- Ian Leitch OTH
- Clare Price OTH
- Judith Robertson OTH (61)
- Lawrence Gozlan NID
- Julia Haller NID (66)
- Michael Sistenich NID
- Daniel Spiegelman NID (62)
- Last Annual
- June 30th, 2025
- Last Interim
- June 30th, 2025
- Incorporated
- October 17th, 1984
- Public Since
- April 9th, 1985
- No. of Shareholders
- 8,660
- No. of Employees
- 5
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 1,231,317,008
- Address
- Suite 0403, MELBOURNE, 3141
- Web
- https://opthea.com/
- Phone
- +61 398260399
- Auditors
- Deloitte Touche Tohmatsu
Similar to OPTEY
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
As of Today at 21:28 UTC, shares in Opthea are trading at $0.02. This share price information is delayed by 15 minutes.
Shares in Opthea last closed at $0.02 and the price had moved by -99.74% over the past 365 days. In terms of relative price strength the Opthea share price has underperformed the S&P500 Index by -99.78% over the past year.
The overall consensus recommendation for Opthea is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreOpthea does not currently pay a dividend.
Opthea does not currently pay a dividend.
Opthea does not currently pay a dividend.
To buy shares in Opthea you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.02, shares in Opthea had a market capitalisation of $518.26m.
Here are the trading details for Opthea:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: OPTEY
Based on an overall assessment of its quality, value and momentum Opthea is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Opthea is $1.00. That is 6456.5% above the last closing price of $0.02.
Analysts covering Opthea currently have a consensus Earnings Per Share (EPS) forecast of -$0.38 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Opthea. Over the past six months, its share price has underperformed the S&P500 Index by -99.59%.
As of the last closing price of $0.02, shares in Opthea were trading -99.48% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Opthea PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Opthea's management team is headed by:
- Jeremy Levin - NEC
- Megan Baldwin - CEO
- Karen Adams - VFN
- Richard Chadwick - OTH
- Mike Gerometta - OTH
- Annette Leahy - OTH
- Ian Leitch - OTH
- Clare Price - OTH
- Judith Robertson - OTH
- Lawrence Gozlan - NID
- Julia Haller - NID
- Michael Sistenich - NID
- Daniel Spiegelman - NID